Trial Profile
Proof-of-concept study of XOMA-213 in patients with hyperprolactinemia
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2016
Price :
$35
*
At a glance
- Drugs XOMA-213 (Primary)
- Indications Hyperprolactinaemia
- Focus Proof of concept; Therapeutic Use
- Sponsors XOMA
- 14 Mar 2016 New trial record
- 09 Mar 2016 According to Xoma Corporation media release, company anticipates initiating this study by mid of 2016.